Celgene’s Abraxane INJ extended its indication to lung cancer after pancreatic cancer

Celgene Korea (CEO Ah-kyung Kim), a global pharmaceutical company specializing in cancer, unveiled on the 31^st that its ‘Abraxane INJ’ acquired an additional approval to add a non-small cell lung cancer indication from the Ministry of Food and Drug Safety.

Abraxane INJ, a primary therapy agent to treat locally progressive or metastatic non-small cell lung cancer with the joint use of carboplat...